PharmaFocus Today – Page 6 – media

Sinopharm Modern Pharmaceuticals’ subsidiary’s Amikacin Sulfate Injection passed the consistency evaluation

On May 13, Sinopharm Modern issued an announcement that recently, its wholly-owned subsidiary Sinopharm Rongsheng Pharmaceutical Co., Ltd. received the “Notice of Approval of Drug Supplementary Application” approved and issued by the National Drug Administration, approving Amikacin Sulfate Injection to pass the generic drug quality and efficacy consistency evaluation. The announcement mentioned that the sales of amikacin sulfate injection in public medical institutions across the country will be 233 million yuan in 2024. So far, Sinopharm Rongsheng has invested approximately 4.59 million yuan (unaudited) in research and development for the consistency evaluation of the drug. In the first quarter of 2025, Sinopharm Modern achieved revenue of 2.607 billion yuan and net profit attributable to shareholders of the parent company of 361 million yuan. https://finance.eastmoney.com/a/202505133403270474.html
- Source: drugdu
- 40
- May 15, 2025
US drug prices will drop by 30%-80% immediately

On the evening of May 11th local time, US President Trump stated on social media that he would sign an executive order at 9 am the next day (9 pm Beijing time on the 12th) with the goal of immediately reducing US prescription drug and medicine prices by 30% to 80%.Image source: Truth Social Trump believes that drug prices in the United States are much higher than in other countries, and the price of the same drug in the United States may be several times that of other countries. This policy mainly includes the implementation of the “most favored nation policy”, allowing the United States to enjoy the same price treatment as the countries with the lowest drug prices in the world, and the US government will renegotiate prices with pharmaceutical companies. If this policy can be implemented, it will greatly reduce the medical burden on the American people, especially ...
- Source: drugdu
- 38
- May 15, 2025
AS treatment! TNF-α declines, IL-17 and JAK open new battlefields!

Some diseases can make people look up at the sky forever, while some diseases can also make people look at the ground forever, and this is ankylosing spondylitis. Regarding the pain points of ankylosing spondylitis (AS), in addition to the spine that is as stiff as if it were poured with cement when you wake up in the morning, this chronic inflammatory disease is like a silent “bone erosion war”, spreading from the sacroiliac joints to the spine, and even affecting peripheral joints such as the hip and knee, eventually leaving the patient in the dilemma of “the body gradually becoming petrified.” This “immortal tumor” is even more despairing to the patient’s biological quality than most terminal illnesses. 4 million people cannot stand up straight all year round Strictly speaking, ankylosing spondylitis (AS) is a refractory chronic inflammatory autoimmune disease that mainly affects the sacroiliac joints, spine, paraspinal soft tissues ...
- Source: drugdu
- 41
- May 15, 2025
Fudan University establishes the “Baili Tianheng Distinguished Professor” program

On the occasion of the 120th anniversary of the founding of Fudan University, Zhu Yi, a 1984 graduate of the Department of Biology and founder, chairman, and chief scientific officer of Sichuan Baili Tianheng Pharmaceutical Co., Ltd., as well as the founder and chairman of Syst Immune, Inc. (Seattle Immunology), donated RMB 30 million in cash to establish the “Fudan University Baili Tianheng Distinguished Professor” project, supporting Fudan University in nurturing a group of outstanding technology leaders in areas such as “Innovative Drug Target Discovery” and “Brain and Brain like Intelligence Research”. Zhu Yi once said in an interview that whether it is basic research or product innovation, real talents are always scarce. The insight and scientific beliefs possessed by innovative talents are important factors in promoting the development of enterprises. The establishment of the “Fudan University Baili Tianheng Distinguished Professor” project is also due to Zhu Yi’s emphasis on ...
- Source: drugdu
- 53
- May 14, 2025
If you don’t lower, don’t sell! Trump enforces minimum drug prices in developed countries, but litigation war may ‘repeat’

If you don’t meet the price, you can’t sell in our country, “said US President Trump at a White House press conference on May 12th, setting the tone for the” Most Favored Nation Pricing “(MFN) policy with a tough stance. This executive order, titled “Pricing Most Favored Nation Prescription Drugs for American Patients,” was signed on May 12th, US time, requiring US drug payment prices to be forcibly anchored to the lowest level in other developed countries within 30 days. This game is destined to be a replay and upgrade of policies in 2020. Four years ago, Trump’s first proposal for the MFN policy was halted by the court, and several industry experts also told Caixin reporters that this litigation war may happen again. Some experts also said that the executive order lacks mandatory measures and whether it can be truly implemented still needs to be observed. The deeper ...
- Source: drugdu
- 48
- May 14, 2025
Barriers and Pathways to Healthtech Adoption in Clinical Practice

Healthtech companies have to navigate a maze of complex regulations, prove their financial model, and win over multiple stakeholders. Finding the right balance between patient protection and innovation is crucial. For many healthtech innovators the real adoption challenge is not always in proving the clinical value of their product. It is overcoming structural barriers that stand in their way. So, let’s explore how these obstacles can be navigated and what healthtech companies need to do to succeed. Regulatory challenges and barriers to entry Overly strict regulations in the healthcare sector, particularly those governing Electronic Health Record (EHR) systems, can stifle innovation by imposing rigid standards that limit flexibility in design and implementation. On one side, their main goal is to promote security, interoperability, and patient safety. In practice, these regulations increase the market power of dominant EHR vendors, such as Epic and Meditech, creating a closed ecosystem that limits ...
- Source: drugdu
- 47
- May 14, 2025
US Health Officials Advise Older Travelers Not to Get a Chikungunya Vaccine

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it investigates possible side effects. The Centers for Disease Control and Prevention and the Food and Drug Administration posted notices late last week on the vaccine, Valneva’s Ixchiq. Chikungunya, spread by the bites of infected mosquitoes, is a debilitating tropical illness marked by fever and joint pain. About 100 to 200 cases are reported annually among U.S. travelers. Last year, the government began recommending the vaccine, which is made with weakened chikungunya virus, to U.S. adults who travel to countries where chikungunya is a problem. But last month, a panel of vaccine experts who advise the CDC heard about an investigation into six people 65 and older — most of them with other medical problems — who became ill with heart or brain symptoms less than a week after vaccination. More ...
- Source: drugdu
- 48
- May 14, 2025
Laimi Pharmaceuticals receives approval for supplemental application for naloxone hydrochloride injection

On May 12, Laimei Pharmaceutical issued an announcement that recently, the company received the “Notice of Approval of Drug Supplementary Application” approved and issued by the State Food and Drug Administration for two specifications of naloxone hydrochloride injection: 1ml:1mg and 2ml:2mg. 　　Naloxone hydrochloride injection is an opioid receptor antagonist, mainly used for the antagonism of respiratory depression after opioid combined anesthesia and the treatment of opioid overdose. 　　According to Yaorongyun data, the market sales of the drug in 2022, 2023 and the first half of 2024 were 420 million yuan, 559 million yuan and 264 million yuan respectively. The approval of this supplementary application means that the company can add new specifications of products, while changing the excipients and production processes in the prescription, further enhancing the market adaptability of the product. 　　In the first quarter of 2025, Laimi Pharmaceutical achieved revenue of 198 million yuan ...
- Source: drugdu
- 48
- May 14, 2025
Rongchang Biopharma’s new drug RC278 clinical trial application accepted

On May 12, Rongchang Biopharma issued an announcement that the company recently received the “Acceptance Notice” approved and issued by the National Medical Products Administration, and the clinical trial application of the new antibody-drug conjugate injection RC278 was accepted. 　　This drug was independently developed by the company and has First-in-Class/Best-in-Class potential. It can specifically identify new tumor targets and exhibit broad-spectrum anti-tumor activity, good safety and pharmacokinetic characteristics. It aims to provide new treatment options for patients with advanced solid tumors. 　　The acceptance number mentioned in the announcement is CXSL2500368, and the application is for the registration of clinical trials of domestically produced drugs. The company’s board of directors bears legal responsibility for the authenticity, accuracy and completeness of the content of the announcement. Although the research and development prospects of the drug are promising, the announcement also reminds investors to pay attention to the high ...
- Source: drugdu
- 41
- May 14, 2025
Major progress in curing hepatitis B

Recently, the annual meeting of the European Association for the Study of the Liver (EASL) is being held. At the conference, BoWang Pharmaceuticals presented the Phase I/IIa clinical research data of its innovative small interfering RNA (siRNA) therapy BW-20507 for the treatment of chronic hepatitis B (CHB) in a poster format. BW-20507 is a siRNA molecule targeting the S region of hepatitis B virus (HBV) messenger RNA developed by Bowang Pharmaceutical based on its independent RNAi platform and unique proprietary technology. This poster summarizes the key research data of BW-20507 monotherapy in the treatment of chronic hepatitis B patients with virological suppression and nucleoside (NUC) naive treatment: BW-20507, administered subcutaneously once every four weeks for three doses, significantly reduced HBsAg levels in a dose-dependent manner, with the maximum reduction observed in the 200 mg and 400 mg dose groups being 2.9~3.2 log10 IU/mL. Among subjects with baseline HBsAg levels less ...
- Source: drugdu
- 45
- May 14, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.